13 September 2022>: Original Paper
Diagnostic Role of Tumor Markers for Hepatocellular Carcinoma in Liver Transplantation Candidates: An Analysis Using the Korean Organ Transplantation Registry Database
Woo-Hyoung Kang 1ABCDE , Shin Hwang 1ABCDEFG* , Jong Man Kim 2BCE , Kwang-Woong Lee 3BDE , Dong Jin Joo 4BDE , Young Kyoung You 5BDE , Je Ho Ryu 6BCE , Bong-Wan Kim 7BDE , Donglak Choi 8BDE , Dong-Sik Kim 9BDE , Yang Won Nah 10BDEDOI: 10.12659/AOT.936937
Ann Transplant 2022; 27:e936937
Table 1 Patient profiles according to the status of HCC and background liver diseases.
Group | All | Viable HCC group | Non-viable HCC group | No HCC group | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case No. | Sex (M: F) | Age (yrs) | MELD score | Case No. | Sex (M: F) | Age (yrs) | MELD score | Case No. | Sex (M: F) | Age (yrs) | MELD score | Case No. | Sex (M: F) | Age (yrs) | MELD score | |
All | 3273 | 2442: 831 | 55.5 ±8.5 | 152 ±9.3 | 2063 | 1697: 384 | 56.7 ±7.6 | 12. 9 ±7.3 | 261 | 206: 55 | 55.7 ±7.3 | 11.0 ±5.8 | 949 | 557: 392 | 52.3 ±10.1 | 21.3 ±10.8 |
HBV | 1953 | 1609: 344 | 55.9 ±7.3 | 13.2 ±8.2 | 1504 | 1272: 232 | 56.1 ±7.1 | 13.4 ±7.3 | 214 | 173: 41 | 55.7 ±6.8 | 10.9 ±6.2 | 235 | 154: 71 | 54.2 ±8.6 | 20.6 ±11.1 |
HCV | 230 | 151: 79 | 58.5 ±7.5 | 14.5 ±7.6 | 188 | 132: 56 | 58.9 ±7.5 | 14.3 ±7.4 | 14 | 9: 5 | 57.0 ±7.4 | 11.4 ±4.1 | 28 | 10: 18 | 57.0 ±7.8 | 17.9 ±9.0 |
ALD | 725 | 534: 191 | 53.6 ±9.3 | 19.8 ±10.2 | 233 | 205: 28 | 57.5 ±8.3 | 14.9 ±6.6 | 28 | 22: 6 | 55.7 ±9.6 | 11.1 ±4.1 | 464 | 307: 157 | 51.3 ±9.1 | 22.8 ±10.6 |
Other | 365 | 148: 217 | 55.8 ±12.3 | 17.2 ±9.8 | 138 | 70: 68 | 69.4 ±9.9 | 13.7 ±7.4 | 5 | 2: 3 | 51.0 ±11.1 | 11.4 ±5.2 | 222 | 146: 76 | 53.7 ±13.1 | 19.4 ±10.5 |
HCC – hepatocellular carcinoma; MELD – model for end-stage liver disease; HBV – hepatitis B virus; HCV – hepatitis C virus; ALD – alcoholic liver disease; M – male; F – female. |